Lead Product(s) : HRS-9821
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : GSK
Deal Size : $12,000.0 million
Deal Type : Licensing Agreement
GSK Strengthens COPD Offering via $12B Biobucks Hengrui Deal
Details : The agreements include an exclusive worldwide license for a potential best-in-class, PDE3/4 inhibitor, HRS-9821 in clinical development for the treatment of chronic obstructive pulmonary disease.
Product Name : HRS-9821
Product Type : Other Small Molecule
Upfront Cash : $500.0 million
July 28, 2025
Lead Product(s) : HRS-9821
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : $12,000.0 million
Deal Type : Licensing Agreement
Reset All
